Skip to main content
search

Children’s Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.

Purpose: To improve the outcomes of patients with T-cell acute lymphoblastic
leukemia (T-ALL) and lymphoblastic lymphoma (T-LL), the proteasome
inhibitor bortezomib was examined in the Children’s Oncology Group phase
III clinical trial AALL1231, which also attempted to reduce the use of
prophylactic cranial radiation (CRT) in newly diagnosed T-ALL.

Close Menu